XML 44 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
SHAREHOLDERS' EQUITY (Tables)
12 Months Ended
Dec. 31, 2023
Stockholders' Equity Note [Abstract]  
Schedule of stock-based compensation expenses
   
Number of options
   
Weighted
average
exercise
price
   
Weighted
average
remaining contractual
life
   
Aggregate
intrinsic
value
 
         
$
   
Years
   
$
 
                             
Options outstanding at beginning of year
   
8,157,749
     
5.43
     
6.32
     
-
 
Options granted
   
1,576,500
     
1.20
                 
Options forfeited
   
(1,086,404
)
   
5.49
                 
Options expired
   
(274,100
)
   
4.92
                 
                                 
Options outstanding at end of year
   
8,373,745
     
4.65
     
6.61
     
1,912
 
                                 
Exercisable at end of year
   
5,017,329
     
5.71
     
5.15
     
117
 
Schedule of option activity
   
Year ended December 31,
 
   
2023
   
2022
   
2021
 
                   
Research and development expenses
 
$
1,933
   
$
2,158
   
$
1,971
 
Marketing and business development expenses
   
(41
)
   
269
     
215
 
General and administrative expenses
   
1,658
     
1,901
     
2,090
 
                         
   
$
3,550
   
$
4,328
   
$
4,276